- MENAP-SMI adds three new board members from Procter & Gamble, Johnson & Johnson, and Bayer.
Dubai, United Arab Emirates – MENAP-SMI (Middle East, North Africa, and Pakistan Self Medication Industry), a non-profit organization representing regional manufacturers of consumer medicines, food supplements and home-use medical devices, today reiterated its ongoing call for enhanced healthcare through responsible self-care, as it released its 2021 action agenda.
MENAP-SMI’s standing mission is to promote better health and wellness throughout the region, by educating the industry and the public on the advantages of diligent self-medication and homebased healthcare. In 2021, the non-profit's Regional Regulatory working group will concentrate on the enhancement of pricing mechanisms for over-the-counter products and the simplification of their registration. It will also work with industry partners to improve E-commerce and digital health regulations in the region.
The organization’s External and Public Affairs working group will continue to promote the value of self-care as the benefits relate to patients and the resources of healthcare systems to build better awareness. While the regional Legal and Compliance working group will work areas such as data privacy, discounting regulations, as well as anti-competition laws.
MENAP-SMI also welcomed three more board members. Procter & Gamble's Commercial Director, Johann Kotze; Johnson & Johnson’s Area VP for Africa, Middle East and Turkey, Makis Kosmatos; and Bayer’s Regulatory Affairs Manager for Gulf and Levant, Mejad Shiyab, all took their seats as the new year’s agenda got underway.
“MENAP-SMI was formed to demonstrate the very real value found in self-care,” said Ashraf Allam, VP for Middle East, Africa, and Turkey at Mundipharma, and Chairman of MENAP-SMI. “If approached responsibly, self-care can deliver significant alleviation to the strain on resources we have seen in recent years throughout the MENAP healthcare industry, heightened by the advent of the global COVID-19 pandemic. This year, we hope to do our part to deliver proof of concept to communities everywhere on how they can take charge of their health and wellness ,and enhance their lives in meaningful and lasting ways.”
Follow MENAP-SMI to stay updated on the latest news and information on self-care.
-Ends-
About MENAP-SMI
MENAP-SMI (Middle East, North Africa, Pakistan Self Medication Industry) is a not-for-profit organization which represents manufacturers of non-prescription medicines, food supplements and self-care medical devices (all also designated as Consumer Health Products), based in the MENAP region. MENAP-SMI is dedicated to promoting better health by the use of consumer health care products where self-care increasingly contributes to better health and more sustainable healthcare systems.
For more information (Press only):
Menapsmi@proglobal.ae (PR Agency)
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
